RANDOMIZED TRIAL OF HIGH-DOSE CYTARABINE VERSUS AMSACRINE IN ACUTE MYELOGENOUS LEUKEMIA IN RELAPSE - A LEUKEMIA INTERGROUP STUDY
Authors:
- WR VOGLERWVWR VOGLER
- HD PREISLERHPHD PREISLER
- EF WINTONEWEF WINTON
- AJ GOTTLIEBAGAJ GOTTLIEB
- J GOLDBERGJGJ GOLDBERG
- J BRENNANJBJ BRENNAN
- H GRUNWALDHGH GRUNWALD
- K RAIKRK RAI
- G BROWMANGBG BROWMAN
- KB MILLERKMKB MILLER
- P CHERVENICKPCP CHERVENICK
- N AZARNIANAN AZARNIA
- 1 April 1986
- journal article
- research article
- Vol. 70 (4) , 455-459
Abstract
Patients with acute myelogenous leukemia in relapse who were ineligible for further anthracycline therapy either because they were judged to be anthracycline resistant or had received the maximum doses were randomized to receive high-dose cytarabine (3 g/m2 every 12 hours for 6 days) or amsacrine (75 mg/m2 daily for 7 days). The response rates in both groups were similar: three of 25 patients given high-dose cytarabine and three of 23 given amsacrine obtained complete remissions.Keywords
This publication has 1 reference indexed in Scilit:
- 4′-(9-Acridinylamino) Methanesulfon-m-Anisidide (AMSA): A New Drug Effective in the Treatment of Adult Acute LeukemiaAnnals of Internal Medicine, 1980